LON:IMM

ImmuPharma Final Earnings Results & Report

ImmuPharma logo
GBX 2.90 +0.49 (+20.37%)
As of 11:58 AM Eastern

ImmuPharma reported Final earnings on May 27, 2026. The company reported EPS of -GBX 0.37.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

ImmuPharma EPS Results

Actual EPS
-GBX 0.37
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ImmuPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

ImmuPharma Final Earnings FAQ

ImmuPharma (LON:IMM) reported earnings of -GBX 0.37 per share for Final. The report was announced on Wednesday, May 27, 2026.

ImmuPharma Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More ImmuPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuPharma and other key companies, straight to your email.

About ImmuPharma

ImmuPharma (LON:IMM) (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

View ImmuPharma Profile